Emily He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emily He has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chuanpeng Dong
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
5 shared publications - Daniyal Mirza
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
5 shared publications - Feifei Zhang
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
5 shared publications - Guangchuan Wang
Chinese Academy of Sciences Center for Excellence in Molecular Cell Science
5 shared publications - Liqun Zhou
Department of Genetics, Yale University School of Medicine, New Haven, USA
5 shared publications - Luojia Yang
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
5 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S21 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Figure S1. AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S2. Dual-AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S3. Quality control of the APCM CRISPR activation screen in the E0771 lung metastasis model. Figure S4. AAV-mediated ORF delivery of immunostimulatory factors elicited antitumor responses. Figure S5. Validation of the six-gene combination CLCG4I in the E0771 metastatic tumor model. Figure S6. Evaluation of IL-12 and IL-23 formation in vitro and in vivo following AAVIL12B treatment. Figure S7. Safety evaluation of AAV-4II treatment. Figure S8. AAV-mediated ORF delivery of immunostimulatory molecules promotes immune cell infiltration into the TME. Figure S9. Gating strategy for analyzing tumor-infiltrating immune cell populations. Figure S10. Comparison of pathway enrichment for the bulk RNA-seq data for tumor cells. Figure S11. Comparison of pathway enrichment in tumor cells between AAV-4II and IFNG from the bulk RNA-seq dataset. Figure S12. Comparative transcriptomic analysis of tumor-infiltrating OT-I T cells across AAV treatment groups. Figure S13. Single-cell transcriptomic profiling reveals 4II-induced transcriptional reprogramming of lung-infiltrating T cells. Figure S14. Cell-cell communication and ligand-receptor interaction analysis in AAV-4II treated tumors. Figure S15. CCL and CXCL signaling pathway network following AAV-4II treatment. Figure S16. Ectopic expression of immunostimulatory factors synergizes with human CART cells. Figure S17. Combining AAV-4II with CAR-T cell enhances anti-tumor activity in human tumor models. Figure S18. Signature gene expression in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S19. Differential pathways in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S20. Elevated 4II signature expression is associated with immunotherapy response. Figure S21. Impact of 4II gene signatures on human patient survival in cancer immunotherapy treatment settings.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S21 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Figure S1. AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S2. Dual-AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S3. Quality control of the APCM CRISPR activation screen in the E0771 lung metastasis model. Figure S4. AAV-mediated ORF delivery of immunostimulatory factors elicited antitumor responses. Figure S5. Validation of the six-gene combination CLCG4I in the E0771 metastatic tumor model. Figure S6. Evaluation of IL-12 and IL-23 formation in vitro and in vivo following AAVIL12B treatment. Figure S7. Safety evaluation of AAV-4II treatment. Figure S8. AAV-mediated ORF delivery of immunostimulatory molecules promotes immune cell infiltration into the TME. Figure S9. Gating strategy for analyzing tumor-infiltrating immune cell populations. Figure S10. Comparison of pathway enrichment for the bulk RNA-seq data for tumor cells. Figure S11. Comparison of pathway enrichment in tumor cells between AAV-4II and IFNG from the bulk RNA-seq dataset. Figure S12. Comparative transcriptomic analysis of tumor-infiltrating OT-I T cells across AAV treatment groups. Figure S13. Single-cell transcriptomic profiling reveals 4II-induced transcriptional reprogramming of lung-infiltrating T cells. Figure S14. Cell-cell communication and ligand-receptor interaction analysis in AAV-4II treated tumors. Figure S15. CCL and CXCL signaling pathway network following AAV-4II treatment. Figure S16. Ectopic expression of immunostimulatory factors synergizes with human CART cells. Figure S17. Combining AAV-4II with CAR-T cell enhances anti-tumor activity in human tumor models. Figure S18. Signature gene expression in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S19. Differential pathways in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S20. Elevated 4II signature expression is associated with immunotherapy response. Figure S21. Impact of 4II gene signatures on human patient survival in cancer immunotherapy treatment settings.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors.Significance:By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors.Significance:By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Next-generation sequencing datasets, including CRISPR screens, bulk RNA-seq, single-cell RNA-seq, and datasets related to adoptive cell therapy (ACT) and immune checkpoint blockade (ICB).
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Next-generation sequencing datasets, including CRISPR screens, bulk RNA-seq, single-cell RNA-seq, and datasets related to adoptive cell therapy (ACT) and immune checkpoint blockade (ICB).
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Source data and statistical analyses for in vivo and in vitro experiments.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Source data and statistical analyses for in vivo and in vitro experiments.
- 27 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (6) , 1222-1244
Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors. Significance: By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- 27 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (6) , 1222-1244
Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors. Significance: By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.